Bone cancer pain

被引:83
作者
Clohisy, DR
Mantyh, PW
机构
[1] Univ Minnesota, Dept Orthoped Surg, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Dept Prevent Sci, Neurosys Ctr, Minneapolis, MN USA
关键词
bone cancer; pain; experimental model; neurochemical markers; osteolytic sarcoma;
D O I
10.1002/cncr.11144
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
BACKGROUND. Bone cancer pain is very common, and patients with this type of pain may be difficult to treat. Development of an experimental model for studying this condition is critical to advancing an understanding of the mechanisms that cause pain in patients with malignant disease. METHODS. A murine model of bone cancer was studied. Combined analysis of the extent Of tumor-induced bone destruction, pain, and neurochemical characterization of the peripheral and central nervous systems was performed to investigate bone cancer pain. Disease-induced bone destruction was assessed by radiographs and histomorphometry. Pain was assessed by spontaneous and elicited behaviors, and neurochemical analysis involved immunohistochemical detection of by hyperalgesic peptides and neurocheinical markers. RESULTS. Mice with distal femoral sarcomas exhibited behavioral and neurocheinical measures of pain. The pain condition created by malignant bone disease was distinct neurochemically from inflammatory and neuropathic pain states. Experimental evidence indicated that both disease-induced osteolysis and tumors themselves contributed to the generation of pain and that peripheral and central sensitization of the nervous system was present. CONCLUSIONS. Malignant bone disease creates a unique pain state that involves sensitization of the nervous system. Major contributors to the pain state within the bone tissue are osteoclastic bone resorption and the malignant disease itself. (C) 2003 American Cancer Society.
引用
收藏
页码:866 / 873
页数:8
相关论文
共 69 条
[1]
Abbadie C, 1997, J NEUROSCI, V17, P8049
[2]
Primary afferent fibers that contribute to increased substance P receptor internalization in the spinal cord after injury [J].
Allen, BJ ;
Li, J ;
Menning, PM ;
Rogers, SD ;
Ghilardi, J ;
Mantyh, PW ;
Simone, DA .
JOURNAL OF NEUROPHYSIOLOGY, 1999, 81 (03) :1379-1390
[3]
Allen BJ, 1997, J NEUROSCI, V17, P5921
[4]
Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: A pilot study [J].
Attal, N ;
Brasseur, L ;
Parker, F ;
Chauvin, M ;
Bouhassira, D .
EUROPEAN NEUROLOGY, 1998, 40 (04) :191-200
[6]
Berruti A, 1999, CLIN CHEM, V45, P1240
[7]
SUBSTANCE-P-IMMUNOREACTIVE AND CGRP-IMMUNOREACTIVE NERVES IN BONE [J].
BJURHOLM, A ;
KREICBERGS, A ;
BRODIN, E ;
SCHULTZBERG, M .
PEPTIDES, 1988, 9 (01) :165-171
[8]
Expression of mRNAs for preprotachykinin and nerve growth factor receptors in the dorsal root ganglion following peripheral inflammation [J].
Cho, HJ ;
Park, EH ;
Bae, MA ;
Kim, JK .
BRAIN RESEARCH, 1996, 716 (1-2) :197-201
[9]
Increased brain-derived neurotrophic factor immunoreactivity in rat dorsal root ganglia and spinal cord following peripheral inflammation [J].
Cho, HJ ;
Kim, JK ;
Zhou, XF ;
Rush, RA .
BRAIN RESEARCH, 1997, 764 (1-2) :269-272
[10]
CLOHISY D, 1999, CLIN ORTHOP RELAT R, P994